ZNTL - Zentalis Pharmaceuticals Inc
IEX Last Trade
3.47
0.220 6.340%
Share volume: 1,566,246
Last Updated: Fri 30 Aug 2024 09:59:59 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$3.25
0.22
6.77%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
8.78%
1 Month
-15.78%
3 Months
-71.01%
6 Months
-77.60%
1 Year
-86.95%
2 Year
-86.48%
Key data
Stock price
$3.47
DAY RANGE
N/A - N/A
52 WEEK RANGE
$2.83 - $27.01
52 WEEK CHANGE
-$0.87
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/04/2024
Company detail
CEO: Kimberly Lynn Blackwell
Region: US
Website: zentalis.com
Employees: 166
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: zentalis.com
Employees: 166
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
developing potentially best-in-class, novel small molecules targeting fundamental biological pathways in cancer
Recent news